About Function Health
Function Health was founded in 2023 by Jonathan Swerdlin and Dr. Mark Hyman, a well-known functional medicine physician and author, based on the thesis that comprehensive, proactive lab testing, covering a much broader range of biomarkers than the relatively limited panel typically ordered during a standard annual physical exam, could help people identify early warning signs of chronic disease, nutritional deficiencies, and other health issues well before they become symptomatic or serious, an approach the company has positioned within the broader "longevity" and preventive health movement that has gained significant mainstream consumer attention and investment in recent years.
Function Health's core membership product gives subscribers access to lab testing covering more than a hundred different biomarkers, spanning categories such as cardiovascular health, hormone levels, metabolic markers, and cancer-related markers, significantly more extensive than what insurance-covered routine physicals typically test, along with a digital platform that helps members understand and track their results over time, including AI-assisted interpretation that flags results outside of optimal ranges and provides context about what a given biomarker means and what steps a member might consider discussing with a healthcare provider. The company has emphasized that its testing and interpretation tools are intended to complement, rather than replace, a member's relationship with their own physician, positioning itself as giving consumers more comprehensive data and proactive visibility into their own health than they would otherwise have access to through the traditional healthcare system's more limited and less frequent testing norms. Function Health grew extremely quickly following its 2023 launch, building a lengthy waitlist and attracting significant consumer interest amid a broader cultural moment of heightened interest in personal health optimization, biomarker tracking, and longevity-focused wellness practices. The company has raised substantial venture funding reaching a valuation in the billions of dollars, reflecting strong investor interest in the fast-growing direct-to-consumer preventive health and longevity testing category, alongside other entrants pursuing similar biomarker-driven health membership models.
